Mainz Biomed (NASDAQ:MYNZ – Get Free Report) was the target of a large decline in short interest in the month of November. As of November 30th, there was short interest totalling 88,000 shares, a decline of 97.5% from the November 15th total of 3,570,000 shares. Based on an average daily volume of 96,100 shares, the days-to-cover ratio is presently 0.9 days. Approximately 5.5% of the company’s shares are short sold.
Mainz Biomed Stock Down 12.2 %
NASDAQ:MYNZ traded down $0.73 on Wednesday, reaching $5.27. 123,861 shares of the company’s stock traded hands, compared to its average volume of 36,855. The firm has a market cap of $1.58 million, a PE ratio of -0.08 and a beta of 0.06. The stock has a 50-day simple moving average of $9.82 and a 200-day simple moving average of $14.35. Mainz Biomed has a 12 month low of $5.10 and a 12 month high of $53.60.
Analyst Ratings Changes
Separately, HC Wainwright lowered Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday, November 25th.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Featured Articles
- Five stocks we like better than Mainz Biomed
- Expert Stock Trading Psychology Tips
- The Great CPU Race: AMD and Intel Battle for Dominance
- When to Sell a Stock for Profit or Loss
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
